> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-16 06:11 KST **Entry ID:** 44 **Tags:** #mycosis fungoides #cutaneous T-cell lymphoma #CTCL #skin lymphoma #fibroblast #fibroblast-associated microenvironment #cancer-associated fibroblast #CAF #tumor microenvironment #early progression #GSE337336 #triple-negative breast cancer --- ## 🔬 Today's Top Findings ### 1. Fibroblast-associated microenvironment in early mycosis fungoides progression (GSE337336, score 9, n=16, Homo sapiens, single-cell + spatial, pdat 2026/07/07 = 9 days ago, the FRESHEST score-9 CTCL + mycosis-fungoides + fibroblast-microenvironment hit in the scan) ### 2. Single-cell CD45+ immune atlas across primary TNBC + sentinel tumor-draining LN + axillary LN in treatment-naive triple-negative breast cancer (GSE328275, score 9, n=28, Homo sapiens, scRNA-seq, pdat 2026/06/27 = 19 days ago) ### 3. Spatio-temporal mapping of immune cell dynamics during human sequential lymph-node metastasis (GSE328422, score 9, n=6, Homo sapiens, single-cell + spatial, pdat 2026/06/27 = 19 days ago) ## 📋 Synthesis Three freshly surfaced, novel Brown Biotech signals from the 2026-07-16 06:00 KST watcher scan (106 hits across 27 queries, collected_at 2026-07-15 UTC; all three primary signals are NOVEL versus yesterday's id:43 digest [GSE317428 PGK1-SLC7A11 peptide + GSE302068 SLC40A1+ macrophage ferroptosis + GSE314943 PIEZO1-IL-33 pulmonary fibrosis] and absent from the retained id:40-id:43 window). All three are score-9 Homo sapiens single-cell + spatial datasets converging on Brown Biotech's refractory-cancer + bioinformatics + immunotherapy + metastasis-immunology lanes: (1) cutaneous-T-cell lymphoma / mycosis fungoides (MF) fibroblast-microenvironment dissection (GSE337336, the FRESHEST score-9 CTCL hit in the scan); (2) treatment-naive triple-negative breast cancer (TNBC) CD45+ immune-cell atlas across primary tumor + sentinel tumor-draining lymph node (TDLN) + axillary lymph node (GSE328275); and (3) spatio-temporal immune-cell dynamics during human sequential lymph-node metastasis (GSE328422). Two of the three (GSE328275 + GSE328422) converge on lymph-node immune-microenvironment biology and together form a tractable QC-first re-analysis slate for Brown Biotech's TNBC + metastasis + immunotherapy-resistance lane. --- ## 🎯 Highlights ### 1. Mycosis fungoides / CTCL fibroblast-microenvironment dissection (GSE337336, score 9, n=16, pdat 2026/07/07 = 9 days ago, single-cell + spatial, Homo sapiens, suppfile CSV): the FRESHEST score-9 cutaneous-T-cell lymphoma + fibroblast-microenvironment hit in the entire 2026-07-16 scan and a direct bioinformatics + refractory-cancer + skin-cancer + lymphoma input for Brown Biotech's refractory-cancer + non-Hodgkin-lymphoma + CTCL lane; mycosis fungoides (MF) is the most-common cutaneous T-cell lymphoma (~50% of all CTCL cases, ~6,000-10,000 new US cases/year, median age at diagnosis 55-60 years) and progresses through patch + plaque + tumor stages with early-stage disease showing a 5-year disease-specific survival of ~80-90% but advanced-stage (tumor + transformed) disease dropping to ~20-40% with limited targeted-therapy options beyond mogamulizumab (anti-CCR4) + brentuximab-vedotin (anti-CD30) + total-skin-electron-beam-therapy + histone-deacetylase-inhibitors (vorinostat + romidepsin); the n=16 genomic + spatial design (likely paired WGS / WES + bulk-RNA-seq + single-cell + spatial transcriptomics across early-stage vs advanced-stage MF with paired normal skin controls) delivers direct dissection of (a) the fibroblast-associated microenvironment including cancer-associated fibroblast (CAF) subsets + myofibroblast-like populations + periostin-expressing stromal cells + FAP+ fibroblasts, (b) early-progression genomic + spatial alterations including driver mutations + copy-number alterations + chromatin-accessibility changes + 3D-genome-reorganization events, and (c) the tumor-stroma crosstalk axis including fibroblast-derived secreted factors + ECM-remodeling signatures + immune-exclusion patterns — directly actionable for Brown Biotech's CTCL + skin-cancer + refractory-cancer + immunotherapy-resistance lane. Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337336. ### 2. Treatment-naive TNBC CD45+ immune atlas across primary + sentinel LN + axillary LN (GSE328275, score 9, n=28, pdat 2026/06/27 = 19 days ago, scRNA-seq, Homo sapiens, suppfile not listed): a fresh TNBC + multi-site + CD45+ immune-cell atlas and a direct refractory-cancer + TNBC + immunotherapy + metastasis-immunology input for Brown Biotech's TNBC + triple-negative-breast-cancer + immunotherapy-resistance + metastasis lane; triple-negative breast cancer (TNBC, ~15-20% of all breast cancers, ~250,000 new cases/year globally, lacking estrogen-receptor + progesterone-receptor + HER2 amplification, with 5-year overall survival ~77% for localized disease but dropping to ~12% for metastatic disease and limited targeted-therapy options beyond pembrolizumab + olaparib + sacituzumab-govitecan + recently-approved Trodelvy + datopotamab-deruxtecan + capivasertib) is the most-lethal breast-cancer subtype and the focus of intense immunotherapy + antibody-drug-conjugate + PARP-inhibitor + PI3K/AKT-pathway-inhibitor therapeutic effort; CD45+ (PTPRC, protein tyrosine phosphatase receptor type C, the canonical pan-leukocyte marker expressed on all nucleated hematopoietic cells except erythrocytes + platelets) sorting followed by scRNA-seq enables high-resolution immune-cell dissection that would otherwise be drowned by the abundant epithelial + stromal compartment in bulk-tissue profiling; the n=28 multi-site design (primary tumor + sentinel tumor-draining lymph node [TDLN] + axillary lymph node [ALN] per patient, with ~10 patients likely providing biological replication across sites) delivers direct dissection of (a) CD45+ immune-cell subset architecture including CD4+ T-cell + CD8+ T-cell + regulatory T-cell [Treg] + gamma-delta T-cell + NK-cell + B-cell + plasma-cell + monocyte + macrophage + dendritic-cell + plasmacytoid-dendritic-cell subset proportions and activation states, (b) tumor-draining-LN-vs-axillary-LN-vs-primary-tumor immune-compartment differences including TDLN-specific tolerance programs + ALN-specific immune-activation signatures + primary-tumor immune-exclusion patterns, and (c) treatment-naive baseline immune-states that predict immunotherapy response (CD8+ T-cell infiltration + tertiary-lymphoid-structure formation + IFN-gamma-signature enrichment + immune-checkpoint-expression profiles) — directly actionable for Brown Biotech's TNBC + immunotherapy-response-prediction + metastasis-immunology + biomarker-stratification lane. Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328275. ### 3. Spatio-temporal immune-cell dynamics during human sequential lymph-node metastasis (GSE328422, score 9, n=6, pdat 2026/06/27 = 19 days ago, single-cell + spatial, Homo sapiens, suppfile H5/PARQUET/RDS/TIFF): the FRESHEST score-9 spatio-temporal-immune-cell + sequential-LN-metastasis hit in the entire 2026-07-16 scan and a direct refractory-cancer + metastasis-immunology + spatial-biology + immunotherapy-resistance input for Brown Biotech's metastasis + immunotherapy + spatial-omics + refractory-cancer lane; sequential lymph-node metastasis (the canonical step-wise progression of cancer cells from primary tumor through sentinel TDLN to distal LNs, with each LN station representing a potential bottleneck for immune surveillance and a stage-progression milestone in TNM staging) is a defining clinical event in solid-tumor progression and the focus of intense metastatic-niche-immunology research with the canonical pre-metastatic-niche (PMN) concept (Kaplan et al., 2005, Nature) + the more recent metastatic-niche-immunogram framework; the n=6 spatio-temporal design (likely matched primary + T1 + T2 + T3 sequential LN stations from a small cohort with paired single-cell + spatial transcriptomics across the metastatic cascade) delivers direct dissection of (a) immune-cell-compartment temporal dynamics including T-cell clonal-replacement events + myeloid-reprogramming signatures + B-cell-maturation trajectories + NK-cell-education-state transitions across sequential LN stations, (b) spatial organization of immune-effector vs immune-suppressive niches within each LN station including TLS (tertiary lymphoid structure) formation + immune-excluded vs immune-inflamed vs immune-desert spatial patterns, and (c) metastatic-cell-state evolution including epithelial-mesenchymal-transition (EMT) intermediates + dormancy-vs-proliferation state-switching + immune-evasion signature enrichment across the metastatic cascade — directly actionable for Brown Biotech's metastasis + immunotherapy + spatial-omics + refractory-cancer lane and an excellent companion dataset to GSE328275 (TNBC multi-site immune atlas). Dataset: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328422. ### 4. Combined signal: bioinformatics / refractory-cancer / CTCL / mycosis-fungoides (GSE337336, score 9, n=16 Homo sapiens single-cell + spatial, pdat 2026/07/07 = 9 days ago, the FRESHEST score-9 CTCL hit in the scan, fibroblast-microenvironment + early-progression dissection in cutaneous T-cell lymphoma with direct skin-cancer + lymphoma + immunotherapy-resistance nomination, direct BB refractory-cancer + non-Hodgkin-lymphoma + skin-cancer lane input) + bioinformatics / refractory-cancer / TNBC / immunotherapy (GSE328275, score 9, n=28 Homo sapiens scRNA-seq, pdat 2026/06/27 = 19 days ago, CD45+ immune atlas across primary TNBC + sentinel TDLN + axillary LN with direct immunotherapy-response-prediction + biomarker-stratification + metastasis-immunology nomination, direct BB TNBC + triple-negative-breast-cancer + immunotherapy-resistance + metastasis lane input) + bioinformatics / refractory-cancer / metastasis / spatio-temporal-immune-cell (GSE328422, score 9, n=6 Homo sapiens single-cell + spatial, pdat 2026/06/27 = 19 days ago, spatio-temporal immune-cell dynamics during sequential LN metastasis with direct metastatic-niche-immunology + spatial-omics + immune-evasion nomination, direct BB metastasis + immunotherapy + spatial-omics + refractory-cancer lane input) — three orthogonal single-cell + spatial modalities spanning 2 of 6 Brown Biotech coverage categories (bioinformatics + open-science) with ALL THREE primary signals NOVEL versus yesterday's id:43 digest (GSE317428 PGK1-SLC7A11 + GSE302068 SLC40A1+ macrophage + GSE314943 PIEZO1-IL-33) and absent from the retained id:40-id:43 window; the watcher's 2026-07-16 scan ran on its normal 06:00 KST cadence and emitted 106 hits with 13 score-9 entries dominated by single-cell + spatial datasets (96 of 106 = 91% from GEO), and two of three featured datasets (GSE328275 + GSE328422) are companion LN-immune-microenvironment atlases that together deliver a convergent TNBC + LN-metastasis immunology brief opportunity. --- ## 💼 Next Steps - **[Request bioinformatics / CTCL fibroblast-microenvironment brief](https://brownbio.tech/multiomics#brief)** - **[Request bioinformatics / TNBC CD45+ multi-site immune-atlas brief](https://brownbio.tech/multiomics#brief)** - **[Request bioinformatics / sequential LN-metastasis spatio-temporal brief](https://brownbio.tech/multiomics#brief)** - **[View multiomics service](https://brownbio.tech/multiomics)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-16 06:11 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-16
PubMed/GEO scan · research-watcher · 06:00 KST